Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. März 2026 13:31 ET | Quelle: Spherix Global Insights

Sickle Cell Care Reaches an Inflection Point as Gene Therapy Enthusiasm Rises, but Referral Pathways and Uptake Lag Amid Due to Treatment Burden

Exton, PA, March 10, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announced the release of its 2026 Patient Chart Dynamix™: Sickle Cell Disease (US) report, an in-depth analysis of 133...
06. März 2026 09:33 ET | Quelle: Spherix Global Insights

Spherix Global Insights Finds Benlysta Exposure Expanding and Rheumatologists Increasingly Turning to Lupkynis in Lupus Nephritis

Exton, PA, March 06, 2026 (GLOBE NEWSWIRE) -- New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape in transition as...
05. März 2026 10:14 ET | Quelle: Spherix Global Insights

Paroxysmal Nocturnal Hemoglobinuria Market Enters Transition Phase as Second-Line Opportunities Expand Amid Ongoing Barriers to Adoption of Newer Agents, According to Spherix Global Insights

Exton, PA, March 05, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announces the release of its latest Market Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing...
05. März 2026 10:14 ET | Quelle: Spherix Global Insights

Paroxysmal Nocturnal Hemoglobinuria Market Enters Transition Phase as Second-Line Opportunities Expand Amid Ongoing Barriers to Adoption of Newer Agents, According to Spherix Global Insights

Exton, PA, March 05, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announces the release of its latest Market Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing...
03. März 2026 08:47 ET | Quelle: Spherix Global Insights

Spherix Global Insights Expands Advisory Capabilities with Launch of a New Market Access Suite of Services

Exton, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announced the launch of a new suite of services focused on Market Access, expanding the company’s advisory capabilities to...
27. Februar 2026 12:31 ET | Quelle: Spherix Global Insights

One in Three Rheumatologists View BMS’ Sotyktu as a Substantial Advance in Psoriatic Arthritis Ahead of March 6 FDA Decision, According to Spherix Global Insights Data

Exton, PA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- With the FDA’s March 6, 2026 PDUFA date approaching for Sotyktu (deucravacitinib) in psoriatic arthritis (PsA), new findings from RealTime Dynamix™:...
24. Februar 2026 08:59 ET | Quelle: Spherix Global Insights

Otsuka Pharmaceutical’s VOYXACT Gains Early Traction in IgAN, with 21% of Nephrologists Reporting Prescribing Within Two Months of Approval

Exton, PA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Two months following the U.S. approval of Voyxact (sibeprenlimab) for IgA nephropathy (IgAN), new data from Spherix Global Insights indicate rapid early...
20. Februar 2026 07:58 ET | Quelle: Spherix Global Insights

Novo Nordisk’s Wegovy® Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity

Exton, PA, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The obesity treatment landscape continues to evolve rapidly as demand for GLP-1–based therapies remains strong and competition intensifies. Novo...
17. Februar 2026 15:24 ET | Quelle: Spherix Global Insights

Gazyva Establishes Early Clinical Credibility in Lupus Nephritis Three Months Post-Approval, According to Spherix Global Insights

Exton, PA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- – Three months into its U.S. launch for lupus nephritis (LN), Roche/Genentech’s Gazyva (obinutuzumab) is entering a treatment landscape shaped not only...
05. Februar 2026 11:40 ET | Quelle: Spherix Global Insights

Spherix Global Insights Reveals Persistent High Disease Burden and Heavy Reliance on Pain Management in U.S. Sickle Cell Disease Despite Awareness of Disease-Modifying Therapies

Exton, PA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- New research from Spherix Global Insights underscores the profound and multifaceted burden faced by patients living with sickle cell disease (SCD),...

Nächste Seite